trial

The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment

NCTId NCT02650102
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Unknown
Enrollment 200 (estimated)
Sponsored by Shanxi Medical University
Primary completion 2016-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Unknown
Enrollment
200 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2013-01
Primary completion
2016-12
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
RisperidoneOlanzapineQuetiapineAripiprazoleZiprasidone

Sponsors

Shanxi Medical UniversityLead Sponsor

Investigators

1
Yong Xu, DoctorPrincipal Investigator

Sites

1 total
Taiyuan, China

Linked catalysts

1
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment — primary completion2016-12

Facts & assertions

4 sourced
Enrollment
200
Phase
PHASE1,PHASE2
Primary Completion Date
2016-12
Status
UNKNOWN
relationships
The graph out of here
drug
Risperidone
drug
Olanzapine
drug
Quetiapine
drug
Aripiprazole
drug
Ziprasidone
drug
lead_sponsor
Shanxi Medical University
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Yong Xu, Doctor
person